TRIP: Translating Research Into Practice

• Sponsor: Boston Medical Center (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03514433
• Collaborator: Boston University (Other), University of Massachusetts, Worcester (Other), Brigham and Women's Hospital (Other), Beth Israel Deaconess Medical Center (Other), Tufts Medical Center (Other), Dana-Farber Cancer Institute (Other), Massachusetts General Hospital (Other)
• Enrollment: 1,224
• Locations: 6
• Arms: 2
• Anticipated Duration (Months): 54.8
• Patients Per Site: 204
• Patients Per Site Per Month: 3.7

Study Details

Study Description

Brief Summary

The TRIP Project aims to overcome barriers to widespread implementation and dissemination of evidence-based practices that will improve the delivery of guideline-concordant care to vulnerable women with breast cancer. To accomplish this goal the study team will create (a) regional patient registries; (b) systematic screening for social barriers to care with a personalized referral plan; and (c) patient navigation services that integrate into one model of care to improve the quality and effectiveness of care delivery, for minority and/or low-income women with breast cancer in Boston.

Condition or Disease	Intervention/Treatment	Phase
Cancer, Breast	Other: TRIP Patient Navigation Intervention	N/A

Detailed Description

This community-engaged program will demonstrate the feasibility of community-academic partnerships to provide innovations in information sharing and systems implementation targeted to reduce treatment disparities. Patient navigators will be able to utilize the patient database to track their patients throughout their treatment, and receive guidance regarding recommended social resources to patients experiencing hardships via the social determinants platform.

Who: The four Massachusetts CTSA hubs (Boston University, Harvard University, Tufts University, and University of Massachusetts) partnered with the Boston Breast Cancer Equity Coalition, and the 6 hospitals that care for women with breast cancer.

Patient population: about1,300 vulnerable inner city women with risk for delay in breast cancer care. Massachusetts (MA) Cancer Registry data identified the following characteristics of Boston residents with greatest delays in breast cancer treatment: Black, Hispanic, non-English speaking, and public health insurance. Six health care institutions care for >90% of these women:

1. Beth Israel Deaconess Medical Center (site PI: Ted James, MD)

2. Boston Medical Center (PI: Tracy Battaglia MD, MPH)

3. Brigham Women's Hospital/Dana-Farber Cancer Institute (PI: Jennifer Haas MD, MPH)

4. Faulkner Hospital (site PI: Rachel Freedman, MD)

5. Massachusetts General Hospital (site PI: Beverly Moy, MD)

6. Tufts Medical Center (PI: Karen Freund MD, MPH)

UMass Medical Center (PI: Stephenie Lemon, PhD) will play an integral role in the planning and implementation of the TRIP intervention but is not a clinical site.

Study Design

• Study Type: Interventional
• Actual Enrollment: 1224 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: A randomized cluster stepped wedge design will be conducted. This pragmatic design involves a sequential, randomized roll-out of the intervention across 6 participating clinical sites or "clusters" over 3 month intervals or "steps". Consistent with a stepped wedge design with one cluster per step, prior to the collection of data in the pre-intervention period, the investigators will generate a set of uniform random numbers for each of the six clusters to assign a starting period for the study intervention. There will be no crossover of patients from usual care to the intervention. That is, patients at each site during the pre-intervention period will experience only usual care and will act as historical controls and those enrolled after the initiation of intervention will experience the intervention.A randomized cluster stepped wedge design will be conducted. This pragmatic design involves a sequential, randomized roll-out of the intervention across 6 participating clinical sites or "clusters" over 3 month intervals or "steps". Consistent with a stepped wedge design with one cluster per step, prior to the collection of data in the pre-intervention period, the investigators will generate a set of uniform random numbers for each of the six clusters to assign a starting period for the study intervention. There will be no crossover of patients from usual care to the intervention. That is, patients at each site during the pre-intervention period will experience only usual care and will act as historical controls and those enrolled after the initiation of intervention will experience the intervention.
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Health Services Research
• Official Title: Translating Research Into Practice: A Regional Collaborative to Reduce Disparities in Breast Cancer Care
• Actual Study Start Date: Aug 6, 2018
• Anticipated Primary Completion Date: Mar 1, 2023
• Anticipated Study Completion Date: Mar 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Historical Control This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
Experimental: TRIP Patient Navigation Intervention This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.	Other: TRIP Patient Navigation Intervention; The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.

Outcome Measures

Primary Outcome Measures

1. Time-to-treatment post-diagnosis [Within 90 days of enrollment]

   The receipt of timely care will be defined as initiation of care within 90 days, as this the shortest delay that has been shown to consistently affect mortality. The time element will be calculated from date of diagnosis (Time0) to date of treatment initiation (Time1) .The date chosen for the Time1 variable will depend on the recommended care plan for each patient, as derived from the chart abstraction and based on patient presentation, including but not limited to stage at diagnosis and co-morbid medical conditions.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. are an adult female 18 years of age or older;

2. reside within 25 miles of the City of Boston;

3. have any of the following risk factors for delays in care: are Black and/or Hispanic ethnicity, do not speak English as their primary language, and/or have only public insurance or are uninsured at the time of diagnosis.

Exclusion Criteria:

1. cancer diagnosis made > 60 days prior to enrollment, such that the ability of the intervention to effect the outcome is limited;

2. presence of a cognitive impairment such as dementia or delirium from any cause (e.g. metabolic, medication or drug induced), given the unique challenges to their treatment decision making/ adherence and the fact that the intervention would not include the patient directly, but rather the family;

3. home residence is outside of the city of Boston, Massachusetts.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tufts Medical Center	Boston	Massachusetts	United States	02111
2	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
3	Boston Medical Center	Boston	Massachusetts	United States	02118
4	Beth Israel Deaconess Medical Center	Boston	Massachusetts	United States	02215
5	Brigham and Women's Faulkner Hospital	Boston	Massachusetts	United States	02215
6	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02215

Sponsors and Collaborators

• Boston Medical Center
• Boston University
• University of Massachusetts, Worcester
• Brigham and Women's Hospital
• Beth Israel Deaconess Medical Center
• Tufts Medical Center
• Dana-Farber Cancer Institute
• Massachusetts General Hospital

Investigators

• Principal Investigator: Tracy Battaglia, MD., MPH, Boston Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Boston Medical Center
• ClinicalTrials.gov Identifier: NCT03514433
• Other Study ID Numbers: H-37314; 1U01TR002070-01
• First Posted: May 2, 2018
• Last Update Posted: Aug 1, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Boston Medical Center: Patient Navigation; Disparity; Social Determinants
• Additional relevant MeSH terms: Breast Neoplasms

Study Results

No Results Posted as of Aug 1, 2022